|
|
Article: Data Demonstrating Aeolus Pharmaceuticals' AEOL 10150's Efficacy as a Broad Spectrum Countermeasure Against Radiological and Chemical Threats Presented at the GHSI Public Health Emergency Medical Countermeasures Workshop.
- Article from:
- Business Wire
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MISSION VIEJO, Calif. -- Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today the presentation of data at the GHSI Public Health Emergency Medical Countermeasures Workshop detailing the potential of AEOL 10150 as a broad spectrum medical countermeasure (MCM) to treat radiological and chemical threats. Data presented from studies sponsored by Aeolus, the National Institutes of Health (NIH), National Institutes of Allergies and Immunological Disorders and NIH CounterACT, highlighted AEOL 10150's efficacy in animal models of Acute Radiation Syndrome (ARS), sulfur mustard gas and chlorine gas exposure.
AEOL 10150 is a broad-spectrum catalytic antioxidant ...